Tumor-infiltrating lymphocyte therapies
Total Trials
25
As Lead Sponsor
As Collaborator
0
Total Enrollment
688
NCT06088472
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 21, 2021
Completion: Dec 31, 2027
NCT06077903
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
Phase: Early Phase 1
Start: Jul 5, 2021
Completion: Jul 31, 2025
NCT05430360
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors
Start: Jan 4, 2022
Completion: May 31, 2025
NCT05430373
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Start: May 23, 2022
Completion: Dec 31, 2025
NCT05729399
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
Phase: Phase 1/2
Start: Sep 14, 2022
Completion: May 1, 2025
NCT06834542
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors
Start: Nov 1, 2022
Completion: Oct 31, 2026
NCT06094426
Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors
Start: Feb 26, 2023
Completion: Feb 26, 2026
NCT06145802
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (gynecological Tumors)
Phase: N/A
Start: Mar 9, 2023
Completion: Mar 9, 2026
NCT06191900
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (advanced Cervical Cancer)
Start: Jun 5, 2023
Completion: Jun 5, 2026
NCT06144671
GT201 Injection For The Treatment Of Advanced Solid Tumors
Start: Sep 13, 2023
Completion: Sep 13, 2026
NCT06235242
GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
Start: Feb 2, 2024
Completion: Jan 31, 2027
NCT06241781
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer
Phase: Phase 2
Start: Apr 2, 2024
NCT06397963
Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients with Solid Tumours
Start: Apr 18, 2024
Completion: Apr 18, 2027
NCT06190275
Clinical Study of GT201 in Combination with PD-1 Inhibitor for Advanced Head and Neck Tumors
Start: May 12, 2024
Completion: Apr 30, 2027
NCT06819280
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Advanced Colorectal Cancer
Start: Jun 28, 2024
Completion: May 27, 2027
NCT06453057
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Solid Tumours
Start: Jul 4, 2024
Completion: Jun 6, 2027
NCT06491225
Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma
Start: Jul 18, 2024
Completion: Jul 18, 2027
NCT06519669
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer
NCT07131254
GT719 Injection for CD19 Positive Recurrent/Refractory Adult B-cell Malignancies
Start: Sep 25, 2024
Completion: Sep 24, 2027
NCT06819293
IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma
Start: Dec 6, 2024
Completion: Dec 7, 2027
NCT07021209
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Start: Jan 14, 2025
Completion: Jan 13, 2028
NCT06948981
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Start: Apr 18, 2025
Completion: Apr 17, 2028
NCT07122076
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Start: Aug 22, 2025
Completion: Aug 21, 2028
NCT07132112
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
Start: Aug 31, 2025
Completion: Aug 31, 2028
NCT07205315
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies
Start: Sep 30, 2025
Loading map...